- Home
- PYN vs BOLD Comparison
PYN vs BOLD Comparison
Compare PYN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- BOLD
- Stock Information
- Founded
- PYN 2002
- BOLD 2018
- Country
- PYN United States
- BOLD United States
- Employees
- PYN N/A
- BOLD 64
- Industry
- PYN Investment Managers
- BOLD
- Sector
- PYN Finance
- BOLD
- Exchange
- PYN Nasdaq
- BOLD Nasdaq
- Market Cap
- PYN 30.1M
- BOLD 24.4M
- IPO Year
- PYN N/A
- BOLD 2024
- Fundamental
- Price
- PYN $5.29
- BOLD $1.17
- Analyst Decision
- PYN
- BOLD Buy
- Analyst Count
- PYN 0
- BOLD 3
- Target Price
- PYN N/A
- BOLD $4.00
- AVG Volume (30 Days)
- PYN 19.9K
- BOLD 283.9K
- Earning Date
- PYN 01-01-0001
- BOLD 08-11-2025
- Dividend Yield
- PYN 5.07%
- BOLD N/A
- EPS Growth
- PYN N/A
- BOLD N/A
- EPS
- PYN N/A
- BOLD N/A
- Revenue
- PYN N/A
- BOLD N/A
- Revenue This Year
- PYN N/A
- BOLD N/A
- Revenue Next Year
- PYN N/A
- BOLD N/A
- P/E Ratio
- PYN N/A
- BOLD N/A
- Revenue Growth
- PYN N/A
- BOLD N/A
- 52 Week Low
- PYN $4.84
- BOLD $1.00
- 52 Week High
- PYN $6.60
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- PYN 49.80
- BOLD N/A
- Support Level
- PYN $5.25
- BOLD N/A
- Resistance Level
- PYN $5.37
- BOLD N/A
- Average True Range (ATR)
- PYN 0.10
- BOLD 0.00
- MACD
- PYN 0.01
- BOLD 0.00
- Stochastic Oscillator
- PYN 9.59
- BOLD 0.00
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.